The New York Eye and Ear Infirmary of Mount Sinai is celebrating 200 years of providing innovative, first-class care to patients with ocular diseases. At the core of the infirmary’s Ocular Oncology Service stands ECF Executive Director Paul T. Finger, MD, who doubles as the committee’s founding director.
The Eye Cancer Foundation has supported much of the research conducted by Dr. Finger in pioneering new methods of treating eye cancers. Since the service began at NYEE in 1989, several new treatment modalities have been adapted: the use of topical chemotherapy in treating conjunctival melanoma and primary acquired melanosis; Finger-Slotted eye plaques to improve local control in treating choroidal melanoma; anti-VEGF therapy in treating intraocular melanoma to lessen radiation damage; and much more.
The support of The Eye Cancer Foundation and the work of the New York Eye and Ear Infirmary has reshaped the face of eye cancer care around the world. The ECF looks forward to continuing its work of supporting research efforts with the end goal of improving patient care.
Read the full article here.
